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It was stronger for the albumin Indicator (R2  11.6, 20.4,Association between prevalent care process measures and facil-
21.8). The fractions of patients falling outside of the Indicatority-specific mortality rates.
guidelines tended to be higher in the highest SMR group. TheBackground. Medical communities often develop practice
groups were not well separated, however, particularly for theguidelines recommending certain care processes intended to
hematocrit and URR Indicators, and there was substantialpromote better clinical outcome among patients. Conformance
overlap between them. Finally, although the likelihood that awith those guidelines by facilities is then monitored to evaluate
facility would be a member of the high or low SMR group wascare quality, presuming that the process is associated with and
associated with fractional variance from Core Indicator guide-can be used reliably to predict clinical outcome. Outcome is
lines, the strengths of association were weak, and the probabil-often monitored as a facility-specific mortality rate (SMR) stan-
ity that a facility would be a member of the high or low groupdardized to the mix of patients treated, also presuming that
could not be easily distinguished from the probability that itinferior outcome implies a suboptimal process. The U.S. Health
would be a member of the middle group.Care Financing Administration monitors three practice guide-
Conclusions. While there were statistical associations be-lines, called Core Indicators, in dialysis facilities to assist man-
tween SMR and the fraction of patients in facilities who wereagement of its end-stage renal disease program: (1) patients’
at variance with these guidelines, they were weak and varianceshematocrit values should exceed 30 vol%, (2) the urea reduc-
from the guidelines could not be used reliably to predict high ortion ratio (URR) during dialysis should equal or exceed 65%,
low SMR. Such findings do not imply that measures reflectingand (3) patients’ serum albumin concentrations should equal
anemia, dialysis dose, or medical processes that influence serumor exceed 3.5 g/dL.
albumin concentration are irrelevant to the quality of care. TheyMethods. The associations of a facility-specific SMR were eval-
do suggest, however, that more attention needs be paid to theseuated with the fractions of hemodialysis patients not conform-
and other associates and causes of mortality among dialysising to (that is, at variance with) the Core Indicators during three
patients when developing care process indicator guidelines.successive years (1993 to 1995) in large numbers of facilities
(394, 450, and 498) using one-variable and multivariable statis-
tical models. Three related strategies were used. First, the asso-
ciation of the SMR with the fraction of patients not meeting Process measures of care, such as the Health Care Fi-
the guideline was evaluated. Second, each facility was classified
nancing Administration’s (HCFA) Core Indicators, areby whether its SMR exceeded the 80% confidence interval
selected measures thought to affect the outcome of careabove 1.0 (worse than 1.0, Group 3), was less than the inter-
[1–3]. They are sometimes monitored within preselectedval below 1.0 (better than 1.0, Group 1), or was within the
interval (Group 2). The fraction of those patients who did not limits hoping to influence the quality and outcome of care
meet the Indicator guidelines was then evaluated in each group. [4]. The Core Indicators were used for that purpose. Thus,
Third, the ability of variance from Indicator guidelines to pre- they should be strongly associated with and predict clini-dict into which of the three SMR groups a facility would be
cal outcome. That is particularly true if they are the maincategorized was evaluated.
or exclusive measures used to judge the care quality amongResults. SMR was directly correlated with variance from the
Indicator guidelines, but the strengths of the associations were facilities. It is necessary, therefore, to understand and dem-
weak particularly for the hematocrit (R2  2.2%, 5.6, and 2.2 onstrate the nature and strength of association between
for each of the 3 years) and URR Indicators (R2  2.6, 0.6, 3.3). outcome and those measures selected for monitoring in
order to ensure that actions taken pursuant to monitor-
ing will likely be effective and efficient in achieving theKey words: HCFA Core Indicators, practice guidelines, quality of care,
statistical evaluation, dialysis, hemodialysis. desired goal: good clinical outcome.
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The clinical and regulatory communities use them widely the subject of the analysis. Each year was evaluated sepa-
rately. A Poisson regression method, used by FMC(NA)to classify facilities according to the percentage of pa-
tients whose values do not conform to the Indicators. for more than ten years, was used to estimate the SMR
for each dialysis unit adjusting for age, gender, race, andHence, we chose them for this initial evaluation before
exploring other potential measures of interest using simi- diabetic status [5].
Facilities were grouped by SMR. Because the confi-lar analytical techniques. The Core Indicators were es-
tablished in 1993 [1–3]. They included statements that (1) dence interval around an SMR of 1.0 depends on the ex-
pected number of incidents (deaths), facilities with smallthe patient’s hematocrit should exceed 30 vol%, (2) the
urea reduction ratio (URR) at which patients are treated patient populations may have wider intervals than facili-
ties with larger patient populations [8]. Thus, a small fa-should equal or exceed 65%, and (3) the patient’s serum
albumin concentration should equal or exceed 3.5 g/dL. cility may have an SMR higher than 1.0 without differing
significantly from it. An identical SMR from a larger unitFacility-specific mortality rates can be described as a
standardized mortality ratio (SMR) by which the number may exceed a confidence interval above 1.0 and thus be
greater than 1.0. Therefore, facilities were grouped ac-of deaths in a dialysis unit during a time period is divided
by the number of deaths that would be expected based on cording to an acceptance range as follows. Group 1 in-
cluded dialysis units for which the facility-specific SMRa profile of patients treated at the unit [5, 6]. Thus, when
the ratio is less than 1.0 the facility experienced fewer was less than the 80% confidence interval below 1.0
considering the facility’s size. They were considered lowdeaths than expected. When it exceeds 1.0 it experienced
more deaths than expected. Government agencies and mortality units. Group 2 included units for which the
SMR fell within the 80% confidence interval aroundothers routinely monitor SMR values for dialysis units
and classify facilities statistically by whether their SMR is 1.0, and they were considered “average” mortality units.
Group 3 included units for which the SMR exceededgreater than expected, lower than expected, or as expected.
We evaluated variance from Core Indicator guidelines, the upper 80% confidence interval over 1.0, and were
considered high mortality units.taken as the fraction of patients treated at a dialysis unit
The Core Indicator guidelines were: (1) the patient’swhose value for the Indicator was outside the guideline,
hematocrit should exceed 30 vol%, (2) the urea reduc-in terms of the SMR for each of 394, 450, and 498 facilities
tion ratio (URR) at which patients are treated shouldduring 1993, 1994, and 1995. Thus, this project sought
equal or exceed 65%, and (3) the patient’s serum albu-to evaluate among facilities the nature and strength of
min concentration should exceed 3.5% g/dL [1–3]. Vari-association between the variance from consensus-estab-
ance from the Core Indicator standard for each facilitylished a priori standards for certain care processes with
during each year was calculated as the fraction of patientsdeviation from the norm of adjusted mortality.
whose median value for the Indicator was less than the
standard. All measurements were performed in a single
METHODS clinical laboratory (LifeChem Clinical Laboratories, Rock-
The dialysis facilities, not the individual patients treated leigh, NJ, USA). Serum albumin concentration was de-
in them, were considered the primary units of analysis. termined by the bromcresyl green method.
We adopted that strategy because the performance of fa- We prosecuted three analytical strategies in one-vari-
cilities is described most often in the aggregate for each able and multivariable statistical models. The first eval-
unit as the fraction of patients not achieving the recom- uated simple bivariate and multivariable associations
mended standard. Similarly, the SMR is a single number between SMR and variances from the Core Indicator
ascribed to the facility as a whole and not to each individ- standards [11]. The SAS Procedures (Cary, NC, USA)
ual patient treated by it. Both of those facility-specific corr and glm were used. The second evaluated the distri-
attributes, however, are estimated by considering values bution of variance from the Core Indicator standards
for the individual patients. in each SMR group. A general linear model was used
The data were taken from the Fresenius Medical Care implemented by the SAS Procedure glm [12]. If there
(North America), Inc. [FMC(NA); Lexington, MA, USA] appeared differences among the means, they were evalu-
patient statistical profile (PSP) system that has been de- ated by Duncan’s multiple range test. A linear discrimi-
scribed previously [7–10]. A major subset of these data was nant function was used to evaluate multivariable models
the subject of an earlier report that compared different and was implemented by the SAS Procedure discrim
methods for estimating an SMR [6]. The data abstraction [13]. The third strategy evaluated the probability of a
techniques are discussed therein. Briefly, adult hemodi- unit being assigned to a particular SMR group depending
alysis patients who were prevalent in or incident to FMC on the percentage of patients at variance from an Indica-
(NA)-affiliated dialysis units during 1993, 1994, and 1995 tor standard. Logistic regression analysis [14] was used
were included in the analysis. Dialysis facilities that were assuming an ordinal target [15, 16]—that is, SMR Groups
1, 2, and 3—using SAS Procedure logistic. Predictionsopen during the entire year of 1993, 1994, or 1995 were
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Table 1. Statistical distribution of measures by yearabout the probability of Group 3 membership from those
models were evaluated by constructing receiver op- 1993 1994 1995
erating curves (ROC) using standard techniques [17]. Number facilities 394 450 498
Patients/facilityThe true positive rate (TPR), or sensitivity, was taken
Mean 98.8 98.9 100.5as the percentage of facilities in Group 3 for which the
1st Quartile 59 57 59
estimated probability of Group 3 membership exceeded Median 89 89 91
3rd Quartile 127 127 131a threshold value. The false positive rate (FPR) was
SMRtaken as the percentage of facilities not in Group 3 for
Mean 1.05 1.07 1.06
which the estimated probability of Group 3 membership 1st Quartile 0.76 0.72 0.71
Median 0.99 0.97 1.01exceeded the threshold value. The predictive value posi-
3rd Quartile 1.20 1.32 1.31tive (PVP) was taken as the percentage of facilities for
Values
which the estimated probability of membership in Group Hematocrit vol %
Mean 31.2 31.5 32.43 exceeded the threshold that were actually in Group 3.
1st Quartile 30.4 30.7 31.7
Median 31.2 31.6 32.4
3rd Quartile 32.0 32.3 33.0RESULTS
URR %
Mean 62.9 64.4 65.7The data
1st Quartile 60.4 62.0 63.8
Table 1 summarizes the statistical distributions of the Median 62.9 64.0 66.0
3rd Quartile 65.7 66.7 67.6measures for each of the three years. The mean and
Albumin g/dLmedian SMR values across facilities were close to 1.0
Mean 3.7 3.8 3.8
and both they and the quantile values were stable across 1st Quartile 3.7 3.7 3.8
Median 3.7 3.8 3.8the years. The SMR for 101, 113, and 136 facilities
3rd Quartile 3.8 3.8 3.9exceeded their confidence interval over 1.0 (that is,
Variances
Group 3) during 1993, 1994, and 1995, respectively. The Hematocrit vol %
Mean 35.4 30.5 20.3SMR for 75, 82, and 92 units exceed the lower interval
1st Quartile 23.1 18.7 12.3(that is, Group 1) during the years.
Median 33.6 27.5 18.6
The distributions of hematocrit, URR, and albumin 3rd Quartile 45.5 40.9 26.9
URR %and the frequency of their variances from the Core Indi-
Mean 60.9 53.1 43.0cator guidelines among facilities suggested an improve-
1st Quartile 42.9 37.4 29.2
ment during this time. For example, the median hemato- Median 63.7 54.9 41.4
3rd Quartile 78.9 69.9 56.6crit among patients increased from 31.2 to 32.4 vol%
Albumin %and the median frequency of variance from standard fell
Mean 25.7 23.0 20.1
from 33.6 to 18.6 among facilities. 1st Quartile 19.4 17.0 15.3
Median 24.7 22.0 19.4The SMR was directly correlated with the fraction of
3rd Quartile 30.0 27.5 23.3patients not meeting the hematocrit standard during 1993,
Abbreviations are: SMR, standardized mortality ratio; URR, urea reduction1994 and 1995. It was directly correlated with the fraction
ratio.
of patients not meeting the URR standard during 1993
and 1995 but not during 1994. The SMR was directly cor-
related with the fraction of patients not meeting the albu-
min standard during each of the three years (Fig. 1). than the lower range of prediction at 40% (0.42). Thus,
the ability to predict the SMR of a dialysis unit fromWhile the SMR was correlated with each of the Indica-
tors, the ability to predict SMR from knowledge of an knowledge of even its albumin Indicator was weak. The
R2 statistic reflects the percentage of the difference ofIndicator value was poor. The outer lines on each graph
of Figure 1 illustrate that ability. They show the 95% pre- SMR values among facilities that can be explained by the
difference of Indicator values. In no case could variancediction limits of the relationships. For example, the slope
of the SMR by albumin variance (lower left panel) sug- from any Core Indicator standard during any year ex-
plain more than 21.8% of the difference of SMR amonggests that there was a 0.017 SMR increase per 1.0%
increase in the fraction of patients not achieving the facilities. The relationships of SMR to the URR and
hematocrit variances were particularly weak.albumin standard. However, while the mean SMR at an
albumin variance of 20% was 0.95, the prediction limits The fraction of patients in a facility not meeting the
hematocrit standard was correlated directly with the frac-spanned a range of SMR from 0.07 to 1.83. The mean
SMR increased to 1.30 when variance doubled to 40%, tion not meeting the URR standard during each of the
three years (R2  6.0%, 6.2%, and 4.3%; all P  0.001).but the prediction limits enclosed a range of SMR from
0.42 to 2.19. The upper prediction range at variance The fraction not meeting the hematocrit standard was
correlated directly with the fraction not meeting the al-equaled 20% (that is, 1.83) and, therefore, was far greater
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Fig. 1. Bivariate regression analyses of the standardized mortality ratio (SMR) on each Core Indicator. The data are presented in graphic format
for 1993 and tabular format for 1994 and 1995. The solid lines indicate the regression line (middle line) and its 95% confidence interval (upper
and lower lines). The outer lines indicate the 95% prediction limits and reflect the ability to predict an individual SMR from knowledge of an
Indicator value. The estimated regression constants for each of the nine analyses are shown below.
Year
Indicator 1993 1994 1995
Hematocrit 0.004 (0.001): 0.901 0.011 (0.002): 0.734 0.008 (0.002): 0.903
URR 0.003 (0.001): 0.847 0.002 (0.002): 0.943 0.006 (0.001): 0.815
Albumin 0.017 (0.002): 0.601 0.034 (0.003): 0.300 0.034 (0.003): 0.374
Data are slope (SE): intercept.
bumin standard in 1994 and 1995 (R2  2.2% and 1.2%; from the Core Indicator hematocrit guideline with SMR
classification. The linear model suggested that differ-both P  0.020); they were not correlated during 1993.
Finally, the fraction of patients not meeting the URR ences in the frequencies of variance from the standard
standard and the fraction not meeting the albumin stan- were not associated with the SMR classification during
dard were correlated inversely during 1993 (R2  1.3%; 1993. SMR classification, however, explained 4.5% and
P  0.020), not correlated during 1994, and correlated 2.4% of the difference between facilities in the frequency
directly during 1995 (R2  2.0%; P  0.002). of variance from the guideline during 1994 and 1995.
During 1995, for example, 17.4% of patients were below
Hematocrit the Core Indicator standard among Group 1 facilities
while 22.5 were below the standard in Group 3 units.Table 2 shows the results of both the linear and logistic
regression analyses evaluating the association of variance The logistic regression analysis suggested that variance
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Table 2. Evaluation of the fraction of patients below the hematocrit increased as the frequency of variance from the standard
standard among specific morality rate (SMR) groups by linear and
increased. The probability of Group 2 membership waslogistic regression analysis
much higher than the others no matter the percentage of
1993 1994 1995 patients not meeting the guideline. Therefore, the hemat-
Linear model ocrit variance was not helpful for evaluating Group mem-
F (P) 1.9 (NS) 10.5 (0.001) 6.0 (0.001)
bership. Similar plots for 1994 and 1995 suggested thatR2 1.0 4.5 2.4
Means a facility more likely would be a member of Group 3 than
Group 1 NA 24.8% 17.4% Group 1 or 2 when the frequency of variance from stan-Group 2 NA 30.1% 20.2%
dard exceeded 70% and 44%, respectively. The R2h valuesGroup 3 NA 35.0% 22.5%
shown in Table 2 suggest that the strengths of thoseLogistic modela
Model R2h % (P) 0.5 (NS) 2.0 (0.001) 1.0 (0.001) associations were weak.
Intercept #1 1.480 1.940 1.552 Figure 2B shows the distribution of hematocrit values
Intercept #2 1.050 0.746 0.958
among the SMR groups during 1993. There was no sig-Hematocrit 0.011 0.026 0.027
nificant difference of mean value among the groups.The linear model is essentially an analysis of variance. “F” means the F statis-
tic. “P” means the probability associate with the null hypothesis of no difference There were significant differences during 1994 (F  8.4,
among the groups. The R2 statistic reflects the extent by which differences in the
P  0.003; Group 1  31.9 vol%, Group 2  31.6 vol%,fraction of patients below the hematocrit standard are associated with SMR group
membership. Groups in a given year that are not accompanied by the same sym- Group 3  31.2 vol%) and 1995 (F  3.8, P  0.023;
bol are significantly different from each other (P  0.05 by Duncan’s multiple
Group 1 32.7 vol%, Group 2  32.4 vol%, Group 3 range test). The R2h statistic of the logistic model reflects the proportion of likeli-
hood of SMR group membership that is associated with the fraction of patients 32.1 vol%; means of Groups 2 and 3 were not signifi-
in a facility whose hematocrit fell below standard. Other estimates are coefficients
cantly different from each other, P  0.05). The rangefrom the model that can be used to estimate the probability of Group membership
from hematocrit variance from standard. of means among Groups 1 through 3 differed by less
a The R2h have been rounded but the P values are actual
than one hematocrit point for each year.
Urea reduction ratio
from the hematocrit standard was not helpful for as- The format for Table 3 is similar to Table 2, except it
signing facilities to an SMR group during 1993. Differ- shows analyses of the URR. The SMR group assignments
ences in the frequency of hematocrit standard variance, explained only about 2.5% of the differences of URR
on the other hand, were associated with 2.0% and 1.0% variance from the guideline among facilities during these
of the likelihood that facilities would be members of a years. Groups 1 and 2 were not different during 1993, nor
particular SMR group in 1994 and 1995. were Groups 2 and 3; only Groups 1 and 3 were signifi-
Figure 2A is taken from the logistic regression analysis cantly different. Groups 1 and 2 were not different in
for 1993 shown in Table 2.1 Curves for the other indica- 1994 and Groups 2 and 3 were not different in 1995. The
tors can be estimated in similar fashion. Table 2 shows logistic regression analyses suggested that differences of
the probability of membership for a facility in each of URR variance from the standard explained about one
the three SMR groups based on the frequency of vari- percent (1%) of the likelihood that a facility would be
ance from the hematocrit standard for patients treated in a member of a particular SMR group.
each facility. The probability of membership in Group 1 Figure 3A suggests that the probability of belonging
decreased and the probability of membership in Group 3 to a high SMR group (Group 3) increased, and the proba-
bility of belonging to the low SMR group (Group 1)
decreased, as the fraction of patients with URR below1 The probability curve as a function of hematocrit can be
calculated as follows: the guideline increased. However, the probability of be-
longing to Group 2 was always much higher than belong-PGp3  {EXP(Intercept #1
ing to either Group 1 or 3 regardless of the fraction of
 Hct coefficient  hematocrit)} patients not meeting the URR guideline. Therefore, the
 {1  {EXP(Intercept #1 URR variance was not helpful in deciding group mem-
bership. Plots for 1994 and 1995 were similar. Hct coefficient  hematocrit)} (Eq. 1)
Figure 3B shows that mean URR tended to be higher
PGp2  {EXP(Intercept #2 among Group 1 facilities and lower among Group 3
 Hct coefficient  hematocrit)} facilities but the differences were not marked. Analyses
for 1994 (F  7.1, P  0.001; Group 1  65.4%, Group {1  {EXP(Intercept #2
2  64.4%, Group 3  63.3%) and 1995 (F  6.4, P 
 Hct coefficient  hematocrit)}  PGp3 (Eq. 2)
0.002; Group 1  66.5%, Group 2  65.8%, Group 3 
PGp1  1  PGp3  PGp2 (Eq. 3) 65.0%; means of Groups 1 and 2 were not significantly
different from each other) were similar. The mean URRwhere P means probability.
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Fig. 2. Probability densities for specific mortality rate (SMR) group membership as a function of the percentage of patients out of compliance
with Core Indicator hematocrit guideline (A) and the distributions of hematocrit (means SE) among the SMR groups (B). F means the F statistic;
P means the probability value for rejecting the Null hypothesis. Means accompanied by the same symbol were not significantly different from
each other (all P  0.05). The data are for 1993.
Table 3. Evaluation of the fraction of patients below the urea the albumin guideline among facilities. All three groups
reduction ratio (URR) standard among specific mortality rate
were significantly different from each other during 1993.(SMR) groups by linear and logistic regression analysis
Only Group 3 had significantly different frequency of
1993 1994 1995 variance from the guideline during 1994 and 1995. Differ-
Linear model ences in the frequency of variances from the albumin guide-
F (P) 4.1 (0.010) 5.6 (0.004) 5.8 (0.003)
line explained from 3.6% to 5.0% of the likelihood thatR2 % 2.3 2.5 2.3
Means a facility would be a member of a particular SMR group;
Group 1 55.0%b 47.5%b 38.1% this was notably higher than the other Core Indicators.
Group 2 60.8%bc 52.6%b 42.9%b
Figure 4 is similar to Figures 2 and 3. The probabilityGroup 3 65.5%c 58.7% 46.5%b
Logistic modela of membership in Group 3 increased sharply as the fre-
Model R2h % (P) 1.0 (0.002) 1.0 (0.001) 1.0 (0.001) quency of variance from the albumin standard increased
Intercept #1 1.905 1.853 1.677
so that it became the most likely group when the frequencyIntercept #2 0.658 0.795 0.831
URR 0.013 0.014 0.016 of albumin variance exceeded about 42%. Plots for 1994
and 1995 were similar, with Group 2 versus Group 3 cross-The linear model is essentially an analysis of variance. “F” means the F statis-
tic. “P” means the probability associate with the null hypothesis of no difference over points occurring at about 39% and 30%, respec-
among the groups. The R2 statistic reflects the extent by which differences in the
tively. The pattern is different from the hematocrit andfraction of patients below the URR standard are associated with SMR group
membership. The R2h statistic of the logistic model reflects the proportion of URR patterns.
likelihood of SMR group membership that is associated with the fraction of
Figure 4B shows that mean serum albumin concentra-patients in a facility whose URR fell below standard. Other estimates are coeffi-
cients from the model that can be used to estimate the probability of Group tion differed among the groups during 1993. It also dif-
membership from URR variance from standard.
fered among them during 1994 (F  16.8, P  0.001;a The R2h have been rounded but the P values are actual
b Groups are not significantly different from each other (P  0.05) Group 1  3.80 g/dL, Group 2  3.77 g/dL, Group 3 
c Groups are not significantly different from each other (P  0.05)
3.68 g/dL; means of Groups 1 and 2 were not significantly
different from each other) and 1995 (F 21.9, P 0.001;
Group 1  3.83 g/dL, Group 2  3.81 g/dL, Group 3 
3.76 g/dL). The difference of mean albumin betweendifference between Groups 1 and 3 differed by 2.1 or
Groups 1 and 3, however, was always less than 0.2 g/dL.less during each of these years.
Multivariable analysesAlbumin
Multiple linear regression analysis of SMR against theTable 4 shows the results of the analyses for serum
three Core Indicators suggested significant associationsalbumin concentration. SMR group membership explained
from 7.6% to 10.4% of the difference in variance from between SMR and the combined Indicators during all
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Fig. 3. Probability densities for specific morality rate (SMR) group membership as a function of fractional variance from the Core Indicator urea
reduction ratio (URR) standard (A) and the distributions of URR (means  SE) among the SMR groups (B). F means the F statistic; P means
the probability value for rejecting the Null hypothesis. Means accompanied by the same symbol were not significantly different from each other
(P  0.05). The data are for 1993.
Table 4. Evaluation of the fraction of patients below the albumin from the URR guideline was not associated with SMR
standard among specific mortality rate (SMR) groups by linear
during 1994, but was during 1993 and 1995. The fractionand logistic regression analysis
of patients below the albumin guideline, on the other hand,
1993 1994 1995 was associated with SMR during all three years.
Linear model Table 6 summarizes the results of the multivariable
F (P) 16.2 (0.001) 20.4 (0.001) 28.8 (0.001)
discriminant function. The analysis was used to assign fa-R2 7.6 8.7 10.4
Means cilities to SMR groups based on variances from the guide-
Group 1 21.7% 19.9%b 17.4%b lines. The assignments were then compared to actual
Group 2 25.4% 21.8%b 18.9%b
SMR group membership. A good model would accu-Group 3 29.3% 27.9% 24.0%
Logistic modela rately assign facilities to their actual SMR groups and
Model R2h % (P) 3.6 (0.001) 4.5 (0.001) 5.0 (0.001) would thereby suggest a high degree of association be-
Intercept #1 2.650 2.775 2.893
tween variance from the guidelines and SMR group. InIntercept #2 0.019 0.003 0.182
Albumin 0.059 0.071 0.090 such cases, values near “100%” would appear in the
The linear model is essentially an analysis of variance. “F” means the F statis- diagonal cells (shown in bold typeface) of the assignment
tic. “P” means the probability associated with the null hypothesis of no difference matrix for each year in Table 6.among the groups. The R2 statistic reflects the extent by which differences in the
fraction of patients below the albumin standard are associated with SMR group. The analysis revealed significant associations between
The R2h statistic of the logistic model reflects the proportion of likeli- variances from the Indicator guidelines and SMR grouphood of SMR group membership that is associated with the fraction of patients
in a facility whose albumin fell below standard. Other estimates are coefficients membership for each year. However, the values for
from the model that can be used to estimate the probability of Group membership Groups 1 and 3 in the diagonals were far from 100% andfrom albumin variance from standard.
a The R2h have been rounded but the P values are actual the error rate exceeded 40% during each year. Group 1
b Groups are not significantly different from each other (P  0.05) and Group 3 facilities were substantially misclassified
into Group 2 based upon their deviations from the Core
Indicators. For example, only 2.7% of Group 1 facilities
were so classified in 1993 while 97.3% were misclassifiedthree years (R2  16.3%, 23.6%, and 23.7%; all P 
as Group 2. Only 8.9% of Group 3 units were so classified0.001; Table 5). Examining the contribution of each Indi-
while 91.1% were misclassified as Group 2.cator (the t statistic) to the models showed that variance
Table 7 shows the results of the multivariable logisticfrom the albumin standard contributed most during each
regression analyses evaluating the probability of assign-year. For example, variance from the hematocrit stan-
ment to the three SMR groups. Those models also sug-dard was not associated significantly with SMR during
gested that the three Core Indicators (except hematocrit1993 or 1995, but was during 1994 after statistical adjust-
ment for its associations with the other Indicators. Variance during 1993) were independently associated with the
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Fig. 4. Probability densities for specific mortality rate (SMR) group membership as a function of fractional variance from the Core Indicator
albumin standard (A) and the distributions of albumin (means  SE) among the SMR groups (B). F means the F-statistic; P means the probability
value for rejecting the Null hypothesis. Means accompanied by the same symbol were not significantly different from each other (all P  0.05).
The data are for 1993.
Table 5. Multivariable models linear regression evaluating the clinical audit. The results are shown in the bottom section
association of specific mortality rate (SMR) with variance
of Table 7.from the Core Indicator standards
The ROC relationships suggested that the associations
1993 1994 1995 between variance from the guidelines and the likelihood
Model F (P) 25.4 (0.001) 46.0 (0.001) 51.2 (0.001) that a facility would be in Group 3 were weak. If one chose
R2 % 16.3 23.6 23.7
a Group 3 probability threshold of 0.1 to audit facilities,t (P): hematocrit 1.8 (NS) 3.6 (0.001) 1.9 (NS)
Urea reduction ratio 3.8 (0.001) 1.4 (NS) 2.6 (0.001) for example, 98% of units in the high SMR group (that
Albumin 7.7 (0.001) 10.3 (0.001) 11.1 (0.001) is, the true positive rate) would be audited. However,
“F” means the F statistic. “t” means the t statistic. “P” means the probability 93.5% (the false positive rate) of facilities in the lowerassociated with the null hypothesis of no difference among the groups. NS means
not significant. The R2 statistic reflect the fraction of the difference among the SMR groups would be audited as well. Only 26.5% (the
SMR that is explained by the combination of the Indicators. predictive value positive) of facilities above the threshold
would actually be in Group 3. If the audit threshold were
increased to 0.3, about one-half (50.5%) of Group 3 units
would be identified but at the expense of auditing nearlylikelihood of a facility being in a particular SMR group.
one-fourth (22.9%) of the acceptable SMR units. LessThe proportion of patients below the albumin standard
than one-half (43.2%) of the units over the 0.3 thresholdwas most predictive of SMR group. These analyses sug-
would actually be in Group 3. If the Group 3 probabilitygest that, while there may be value in considering the
threshold for audit were increased to 0.4, 65.8% of the 44indicators as a composite, the combination of indicator
units over the threshold would be in Group 3 (the PPV).variances from the guidelines explain only 5.1% to 7.2%
However, only 24.7% of facilities actually in Group 3of the likelihood that a facility will fall into a particular
would be identified and more than three-fourths of facili-SMR group.
ties with a high SMR score would escape undetected.The statistical models summarized in the top of Table 7
To further illustrate how poorly even the combinedwere used to estimate the probability of membership in
indicators diagnose high SMR, a year and threshold com-Group 3 for each facility during each year from their var-
bination associated with a high PPV could be selected.iances from the Core Indicators. ROC were constructed
Thirty-four facilities exceed the 0.5 threshold for Group 3for each year to determine if there existed an estimated
membership during 1995 and 24 of those were actuallyGroup 3 probability that would distinguish actual Group
in Group 3 (PPV  70.6%). Ten of 362 facilities were3 membership from membership in Groups 1 or 2. If so,
such an estimate could be used to select facilities for misclassified into Group 3, giving an FPR of 2.7%. Of
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Table 6. Multivariable linear discriminant function models evaluating the association specific morality rate (SMR)
group with variance from the Core Indicator standards
1993 1994 1995
Model F (P)
7.7 (0.001) 10.9 (0.001) 11.2 (0.001)
Model assignments
from ↓ : to →a Gp 1 Gp 2 Gp 3 Gp 1 Gp 2 Gp 3 Gp 1 Gp 2 Gp 3
Group 1 2.7 97.3 0.0 0.0 98.2 1.2 0.0 94.6 5.4
Group 2 0.5 94.5 5.0 0.4 96.1 3.5 0.0 94.8 5.2
Group 3 0.0 91.1 8.9 0.0 83.2 16.8 0.0 78.7 21.3
Error rate % 44.9 41.3 42.8
“F” means the associated F statistic. “P” means the probability associated with the null hypothesis of no difference among the groups. 	 means a coefficient. 
2
means the Chi-square statistic.
a As a percentage (%) of the “From” groups. Thus, each row within each year will add to 100%. The diagnosis for each yearly assignment matrix are shown in
bold typeface. Ideally, each value therein should approach 100%. See text for details.
Table 7. Multivariable logistic models evaluating the association of specific morality rate (SMR) group
with variance from the Core Indicator standards
1993 1994 1995
5.1 (0.001) 7.2 (0.001) 5.9 (0.001)
Model R2h (P) 	 
2 P 	 
2 P 	 
2 P
Intercept #1 4.043 64.7 0.001 4.369 91.3 0.001 3.619 89.4 0.001
Intercept #2 1.289 8.0 0.005 1.461 13.1 0.001 0.905 7.0 0.008
Hematocrit 0.006 0.7 NS 0.022 11.6 0.001 0.020 6.2 0.013
Urea reduction ratio 0.016 12.5 0.001 0.013 8.5 0.001 0.010 4.1 0.044
Albumin 0.066 31.7 0.001 0.078 38.2 0.001 0.086 28.9 0.001
Probability of
Group 3 TPR FPR PVP N TPR FPR PVP N TPR FPR PVP N
0.0 (All) NA NA NA 394 NA NA NA 450 NA NA NA 498
0.1 98.0 93.5 26.5 373 97.3 88.7 26.9 409 100.0 95.7 28.4 479
0.2 81.2 52.6 34.7 236 73.4 46.9 34.4 241 84.6 58.8 35.1 328
0.3 50.5 22.9 43.2 118 51.3 22.0 43.9 132 51.5 28.4 40.5 173
0.4 24.7 6.5 65.8 44 33.6 8.0 58.5 65 30.1 9.9 53.2 77
0.5 8.9 3.7 45.0 20 16.8 3.0 65.6 29 17.6 2.7 70.6 34
0.6 3.0 2.0 33.3 9 10.6 1.2 75.0 16 9.6 1.4 72.2 18
R2h means Harrell’s statistic that is similar to the R2 statistic in ordinary linear regression. “P” means the probability of no association between SMR grouping and
the combined (R2h) or individual (
2) indicators. 	 is a regression coefficient. 
2 is the chi-square statistic. Abbreviations are: TPR, true positive rate; FPR, false posi-
tive rate; PVP, predictive value positive; all given as percentages; N, the number of facilities in the group. The TPR, FR, and PVP apply to facilities exceeding the
indicated probability.
the 136 facilities actually in Group 3, 24 were correctly health care systems [19, 20], subpopulations of patients
in those systems [21], and to individual facilities to judgeclassified [Sensitivity (TPR) 17.6%] while 112 (82.4%)
quality of care. Therefore, clinicians and care quality mana-were incorrectly diagnosed as having an adequate SMR.
gers should understand thoroughly the nature and strengthIn other words, the sensitivity of this multivariable model
of the associations between the measurements they useto identify Group 3 membership was very low when the
to monitor and judge care among facilities. That is partic-probability threshold was high, even if the PPV appeared
ularly true for the measures that are thought to reflectattractive. Thus, these findings and those of the discrimi-
the outcomes and processes of care. This project evalu-nant function analysis are comparable.
ated the association of aggregate outcome at the facility
level with consensus-based aggregate process measures
DISCUSSION among facilities. We chose that approach because there
Practice measures, like the Core Indicators, frequently have been few, if any, studies demonstrating robust asso-
arise from processes like the National Kidney Founda- ciations between such aggregated process measures and
tion sponsored Dialysis Outcome Quality Initiative [18]. outcomes judged at the facility level rather than at the
They are most often based on medical literature evaluat- level of individual patients.
ing the associations between outcome and care processes Each Core Indicator measure was associated with the
among individual patients. The guidelines are then fre- facility mortality profile as judged by the SMR. That was
true whether the association was evaluated as a simplequently applied to the aggregate performance of entire
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bivariate correlation, the distributions of the Indicators during a year, particularly in small facilities, could lead
among facilities categorized by the SMR, or whether to random variation of the SMR within some confidence
values of it were associated with the likelihood that a interval even though a measure, such as the URR, is asso-
facility would fall in a particular SMR group arranged ciated with death risk among individual patients in larger
from low mortality to high. However, the strength of the samples. Our purpose here was to evaluate facility-based
associations between the hematocrit and URR Indica- associations between the SMR, a measure of outcome,
tors were weak. Those two indicators, evaluated over and care process measures selected by others. It was not
three years each, explained only 0.6% to 5.6% (median, to evaluate once more the association of hematocrit,
N  2.4%) of the difference of SMR among facilities. URR, or albumin with death risk among patients. Thus,
One might argue that URR, hematocrit and albumin potential statistical artifacts that could account in part
are all associated with mortality. The consensus-based for lack of an association do not change the fact that
thresholds are simply not optimal. Our purpose, how- clinicians and quality managers cannot simply assume a
ever, was to evaluate a priori criteria decided by others. strong association between the measures. Finally, we
The Core Indicators are based on designated thresholds grouped facilities according to whether they were inside
and do not treat the measures as continuous variables. or outside of facility-specific confidence intervals and
Categorizing facilities by SMR explained less than 5% evaluated the distributions of variance from the Core
of the distribution of those indicators during the years Indicators in them. Those analyses considered facility
(median, N  2.5%). Furthermore, differences of aver- size, thereby reducing the likelihood of such misclassifi-
age variance from the Indicator standards among the cation errors.
SMR groups tended to be relatively small. The fraction of Second, averaging measures by center ignores the po-
patients below the hematocrit standard among facilities tential statistical variance within the centers. The SMR,
with low mortality during 1995 was 17.4%; it was 22.5% however, is of necessity such a facility-specific measure
among facilities with the highest mortality, which is only of aggregate performance. Further, our aim was to evalu-
a 5.1 percentage point difference. Similar statistics for ate a priori measures of aggregate facility performance.
the URR were 38.1% and 46.4%, only an 8.3 percentage The Core Indicators as formally stated contemplate no
point difference. Finally, these two indicators each ex- dispersion of measures within units except whether pa-
plained only 1% or 2% of likelihood that a facility would tients do or do not comply with them.
be a member of particular SMR groups. Thus, we con- Third, basing our analyses on the percentage of pa-
clude from all three of these analytical approaches that tients not meeting a standard rather than some other
the association between these two Core Indicators and statistical measure, such as a mean or median value,
the facility-specific SMR is statistically significant, but
dichotomizes the measures that might reduce their ex-
too weak to be practically useful for predicting the SMR.
planatory power. This possible objection is related toOf the Core Indicators, aggregate facility outcome was
the second analysis just discussed. The Core Indicatorsbest associated with the fraction of patients below the al-
as conceived force dichotomization and our purpose wasbumin standard. Variance from the albumin standard
to evaluate existing measures, not develop new ones.explained up to 20% of the difference in SMR among
Fourth, the strengths of association for hematocrit,facilities. Categorizing facilities by SMR explained from
URR, and albumin with risk may be weaker than is com-7.5% to 10.4% of the differences in variance from the al-
monly assumed. That is likely so. The URR, for example,bumin standard among facilities. However, like the vari-
has become much less strongly associated with deathances from the hematocrit and URR standards, the nu-
risk over time [22] and the apparent thresholds associ-merical difference among the SMR groups was small.
ated with “adequate treatment” appear to have changedThe fraction of patients below the albumin standard
[23]. While serum albumin concentration has alwaysamong facilities with low mortality during 1995, for ex-
been strongly associated with death risk, hematocrit hasample, was 17.4%; it was 24.0% among facilities with the
been much more weakly associated [9, 22, 24, 25]. Fur-highest mortality, which is a difference of only 6.6 per-
thermore, statistical models incorporating substantialcentage points. Finally, variance from the albumin stan-
numbers of demographic and laboratory measures rarelydard was associated with only 4% to 5% of the likelihood
explain more than 25% of the likelihood of survivalthat a facility would be a member of a particular SMR
among patients. They most commonly explain less thangroup. Thus, we conclude that while variance from the
20% and often explain only 10% to 15% (unpublishedalbumin standard was the strongest associate of SMR,
observations) [9, 26]. Thus, there are many factors influ-the differences among facilities was probably insufficient
encing the survival of patients that are not consideredto permit meaningful judgments about the SMR.
by statistical models commonly used to evaluate deathThere are several statistical reasons that might explain
risk. Therefore, there is no reason to believe that thethe weak association between the SMR and these Core
Indicators. First, random variation in the number of deaths Core Indicator descriptions of only three laboratory mea-
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sures should prove to be strong and robust predictors SMR. Serum albumin concentration is also a well-known
of aggregate mortality among facilities. and powerful associate of death risk among patients
The Core Indicators are generally used as separate, [6–8]. Inadequate nutritional status is also described by
distinct, and independent measures, rather than being com- such measures as serum creatinine concentration and
bined in a multivariable sense, to judge facilities’ perfor- anthropometric body size [8, 9, 28]. However, chronic
mances. Even when they are taken together in multivari- inflammatory states contribute to hypoalbuminemia
able statistical models, however, they explain less than among dialysis patients [29–31]. Therapies shown by ret-
one-fourth of the SMR difference among facilities. The rospective studies to be effective for increasing serum
ability of the discriminant function and logistic models albumin concentration and reducing death risk [32–34]
to classify facilities into SMR groups based on variances are no longer approved for payment in the United States
from the Core Indicators was weak. Thus, we must con- and thus are not available to the majority of patients.
clude that even when taken together, the Core Indicators Therefore, there is no approach to management of vari-
are weakly associated with clinical outcome as judged ance from that Core Indicator most closely associated
by the SMR and that the albumin guideline is the most with outcome. The quality improvement paradigm re-
important of the Indicators. quires research to understand and treat important associ-
There are at least two implications of these findings
ates of risk so that effective therapy can be made avail-
as they apply to quality improvement programs. The
able to patients [35, 36]. Finally, the combined Corefirst involves the likely magnitude of the effect and the
Indicators explain relatively little of the difference inefficiency of trying to manipulate the care processes, as
SMR among facilities. The quality improvement para-judged by these Indicators, on the aggregate outcome
digm also requires that evaluation of the leading contrib-of care. The investigative and therapeutic strategies that
utors to mortal risk be determined and evaluated, andlogically follow from these observations are the second.
that therapeutic strategies be developed to manage themActions taken solely to improve compliance with a
[35, 36].Core Indicator threshold—particularly the URR and he-
There are several qualifications that require discus-matocrit thresholds—are not likely to have a dramatic
sion. First, the FMC(NA)-affiliated facilities and the pa-effect on aggregate outcome in terms of the SMR be-
tients treated in them may not be fully representative ofcause the strengths of association between them and the
the general population in the United States. However,SMR are weak. While these thresholds for hematocrit,
the sample sizes and demographics of these FMC(NA)URR, and albumin may be suboptimal, other medical
processes not considered by the Core Indicators likely cohorts support such a generalization [6]. Furthermore,
have substantial influence on clinical outcome. the purpose of this project was only to test a priori stan-
Similarly, a high SMR may not imply poor care process dards in a large group of facilities, and we make no claim
as defined by these practice guidelines. Therefore, other that they fully represent any other population.
unmeasured attributes and processes contribute more Second, there are many ways to estimate an SMR par-
to clinical outcome than the processes that the Core ticularly with respect to the qualities selected for stan-
Indicator thresholds reflect. Examples of such unmeas- dardization and the choice of the reference population.
ured processes might include the management of cardio- We have evaluated and discussed those matters else-
vascular disease or the choice of vascular access type by where [6]. The reference population is fully representa-
physicians. Similar to these findings, Park and co-authors tive of the facility populations here and no patient classes
found that identifying hospitals with poor cardiac care were excluded from consideration. The standardizing
processes using death rate classifications was quite diffi- quantities (age, gender, race, and diabetic status) are
cult [27]. Presumably factors other than the measured
non-controversial and are similar to those chosen by the
processes influenced the rates.
United States Renal Data System [5].While clinicians have well-established tools to assist
Third, our choice of the 80% confidence interval aboutin increasing the hematocrit (for example, the exogenous
which to group facilities was arbitrary. Some investiga-administration of erythropoietin and iron) and the URR
tors might choose another value. Our goal was to choose(such as increasing the size of a dialyzer or increasing the
a practical value that would permit reasonable numberslength of dialysis sessions), uniformly effective therapies
of facilities in each of the three groups to enhance statis-for increasing serum albumin concentration are not avail-
tical stability. Group 3 units represented 25.6%, 25.1%,able. Therefore, the evidence suggests that a regulatory
and 27.3% of all facilities during 1993 through 1995,focus on these Indicator measures as a system-wide qual-
respectively. Similar values for Group 1 were 19.0%,ity improvement strategy likely will not yield dramatic
18.2%, and 18.5%.benefit in terms of reduced mortality.
Fourth, some might argue that the URR is a subopti-Variance from the albumin standard, a presumed proxy
for nutritional status, was most closely associated with mal measure of dialysis dose [9]. Our purpose here, how-
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